Fulminant type 1 diabetes caused by peginterferon α-2a therapy in hepatitis C

J Diabetes. 2018 May;10(5):419-420. doi: 10.1111/1753-0407.12636. Epub 2018 Feb 5.

Authors

Ying Zheng¹, Zhen Wang^{2

3}, Zhiguo Xie^{2

3}, Ruchun Dai^{2

3}, Zhiguang Zhou^{2

3}

Affiliations

¹ Center for Medical Research, Second Xiangya Hospital, Central South University, Changsha, China.
² Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China.
³ Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China.

PMID: 29265717
DOI: 10.1111/1753-0407.12636

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antiviral Agents / adverse effects*
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / pathology
Female
Hepacivirus / drug effects*
Hepatitis C / drug therapy*
Hepatitis C / virology
Humans
Interferon-alpha / adverse effects*
Middle Aged
Polyethylene Glycols / adverse effects*
Prognosis
Recombinant Proteins / adverse effects

Substances

Antiviral Agents
Interferon-alpha
Recombinant Proteins
Polyethylene Glycols
peginterferon alfa-2a